Basque enterprise blog Receive daily information of interest to your company

17 June, 2019
VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office

LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells.

LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells.

 

VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.

 

LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells. This novel mechanism of action provides advantages relative to safety and efficiency with respect to the vectors currently in use.

 

When its development phase ends, the advantages of LENTISOMA will position it as one of the vectors of choice for the gene therapies that require it.

 

Therefore, it is very important that LENTISOMA is correctly protected from the Intellectual Property point of view in the United States, bearing in mind that it is the most powerful country in the development of gene therapies.

 

This concession is consistent with the growing number of manufacturing projects that VIVEbiotech is developing in the US market (6 projects currently).

 

Entrepreneurship 1 November, 2021
‘Syngoi Technologies’: Columbus VP creates a new company in Bizkaia for synthetic DNA production

Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology...Read more

Entrepreneurship 12 November, 2020
Meet the 72 Industry 4.0 Startups most valued by the BIND 4.0 Partner Companies and the Finalists for the 5th Edition of the Program

Next January the Participants will be announced and the acceleration program will begin. 20 of...Read more

Entrepreneurship 3 February, 2020
VIVEbiotech SL new member of the Board of Directors of the Spanish Bioindustry Association (AseBio)

AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Read more

Linkedin

Daily information segmented according to business
sectors and countries of interest to make the most competitive
decisions

Latest news about New Subsidies

For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.

You’re interested, right?